ArticleDigestive diseases and sciences2025
20-Year Mortality in a Population-Based Cohort of Patients with Inflammatory Bowel Disease from New Zealand.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- All-cause and cause-specific mortality in inflammatory bowel disease across the biologic era: a population-based matched cohort study.Journal of Crohn's & colitis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInflammatory bowel disease (IBD) can lead to mortality directly through severe disease or indirectly via increased risk of malignancy or infection. There are few studies of IBD mortality from the Southern Hemisphere, while new treatments have become available. We aimed to measure 20-year mortality from a population-based IBD cohort in Canterbury, New Zealand.
methodsA prevalent cohort of 1420 patients with IBD and 600 controls, both recruited in 2005, were followed to 2024. Medical record review identified the underlying cause of death. Standardized mortality ratios compared the deaths in the IBD cohort with those in the general population. Risks were assessed using hazard ratios from Cox regression analysis.
resultsDuring the 23,558 person-years of follow-up, 366 (25.9%) patients with IBD died, at an average age of 75.3 years (SD 13.7). More patients with ulcerative colitis (UC) (n = 195; 29.4%) than Crohn's disease (CD) (n = 162; 22.8%) died. Fewer (18.4%) of the matched control participants died. The SMR for IBD was 1.23 (95% CI 1.11-1.36), with the SMR for CD being 1.42 (1.21-1.65) and UC 1.18 (1.02-1.35). Older age and primary sclerosing cholangitis (PSC) were associated with an increased risk of mortality. Smoking was associated with CD mortality and cancer with UC mortality. Common causes of death included cancer, heart disease, and pneumonia.
conclusionPatients with IBD from this population-based cohort were at increased risk of all-cause mortality over the 20-year follow-up. CD had a higher mortality rate than UC and patients with concomitant PSC were at particular risk.
Indexed as
Identifiers
40591228What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.